TR200200027T2 - İntergrin alfa-4 alt-biriminin bir antagonisti kullanılarak fibrozun tedavisi. - Google Patents

İntergrin alfa-4 alt-biriminin bir antagonisti kullanılarak fibrozun tedavisi.

Info

Publication number
TR200200027T2
TR200200027T2 TR2002/00027T TR200200027T TR200200027T2 TR 200200027 T2 TR200200027 T2 TR 200200027T2 TR 2002/00027 T TR2002/00027 T TR 2002/00027T TR 200200027 T TR200200027 T TR 200200027T TR 200200027 T2 TR200200027 T2 TR 200200027T2
Authority
TR
Turkey
Prior art keywords
fibrosis
antagonist
treatment
subunit
intergrin
Prior art date
Application number
TR2002/00027T
Other languages
English (en)
Inventor
Gotwals Philip
R. Lobb Roy
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of TR200200027T2 publication Critical patent/TR200200027T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Bir insan ya da hayvan sujede fibrozun tedavisi için bir yöntem anlatilmistir. Bu yöntem, sujeye, VLA-4 integrin ya da fragmanina bir antagonistin etkili bir miktarinin tatbik edilmesini içermektedir.
TR2002/00027T 1999-04-22 2000-04-21 İntergrin alfa-4 alt-biriminin bir antagonisti kullanılarak fibrozun tedavisi. TR200200027T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13084799P 1999-04-22 1999-04-22
US13721499P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
TR200200027T2 true TR200200027T2 (tr) 2002-07-22

Family

ID=26828876

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00027T TR200200027T2 (tr) 1999-04-22 2000-04-21 İntergrin alfa-4 alt-biriminin bir antagonisti kullanılarak fibrozun tedavisi.

Country Status (31)

Country Link
US (3) US6652856B2 (tr)
EP (1) EP1173201B1 (tr)
JP (3) JP5483515B2 (tr)
KR (3) KR20070102760A (tr)
CN (3) CN1332714C (tr)
AT (1) ATE298249T1 (tr)
AU (1) AU783054B2 (tr)
BG (2) BG65578B1 (tr)
BR (1) BR0010669A (tr)
CA (1) CA2370814C (tr)
CY (1) CY1106046T1 (tr)
CZ (1) CZ301636B6 (tr)
DE (1) DE60020955T2 (tr)
DK (1) DK1173201T3 (tr)
EA (1) EA006681B1 (tr)
EE (1) EE05662B1 (tr)
ES (1) ES2243259T3 (tr)
GE (1) GEP20063844B (tr)
HK (1) HK1041452B (tr)
HU (1) HU226383B1 (tr)
IL (5) IL145898A0 (tr)
IS (1) IS2259B (tr)
MX (1) MXPA01010612A (tr)
NO (1) NO330221B1 (tr)
NZ (2) NZ541431A (tr)
PL (1) PL198975B1 (tr)
PT (1) PT1173201E (tr)
RS (2) RS50086B (tr)
SK (1) SK287328B6 (tr)
TR (1) TR200200027T2 (tr)
WO (1) WO2000064474A1 (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1173201E (pt) * 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
DK2314315T3 (en) 1999-06-01 2015-02-02 Biogen Idec Inc Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
GB0013674D0 (en) * 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
EP1278517B1 (en) * 2000-03-17 2007-05-30 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
MXPA03009390A (es) * 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1689780A2 (en) * 2003-10-17 2006-08-16 University Court of the University of Edinburgh Tissue repair by modulation of beta-1 integrin biological function
WO2005079314A2 (en) * 2004-02-13 2005-09-01 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
US20080286251A1 (en) * 2004-08-02 2008-11-20 Propharmaceuticals, Inc. Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
EP2839843B1 (en) * 2006-05-25 2018-06-20 Biogen MA Inc. VLA-1 antagonist for use in treating stroke
ES2402334T3 (es) * 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
WO2013147076A1 (ja) * 2012-03-28 2013-10-03 国立大学法人広島大学 インテグリンα8β1の機能を阻害する事による線維化の抑制
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
WO2019163927A1 (en) * 2018-02-23 2019-08-29 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent tgf-beta 1 antibodies and methods of use
CN120025435A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
WO1993013798A1 (en) * 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
ES2114183T5 (es) * 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
AU703152B2 (en) * 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DK0759302T3 (da) * 1994-04-26 2000-11-13 Kanebo Ltd Middel mod rheumatoid arthritis
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
JPH10330268A (ja) * 1997-05-26 1998-12-15 Kureha Chem Ind Co Ltd ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤
US20020004482A1 (en) * 1997-08-08 2002-01-10 Xiaozhu Huang Treatment of acute lung injury and fibrosis with antagonists of avbeta6
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
PT1173201E (pt) * 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Also Published As

Publication number Publication date
EE200100549A (et) 2002-12-16
JP2002542300A (ja) 2002-12-10
CY1106046T1 (el) 2011-04-06
YU74901A (sh) 2004-07-15
EA006681B1 (ru) 2006-02-24
IL206830A (en) 2013-06-27
CN1679935A (zh) 2005-10-12
IL145898A (en) 2007-07-24
CN1332714C (zh) 2007-08-22
BG66149B1 (bg) 2011-08-31
JP5483515B2 (ja) 2014-05-07
GEP20063844B (en) 2006-06-12
DE60020955D1 (de) 2005-07-28
CA2370814C (en) 2010-07-06
RS50086B (sr) 2009-01-22
KR100746522B1 (ko) 2007-08-07
NZ541431A (en) 2008-01-31
US6652856B2 (en) 2003-11-25
BG106118A (en) 2002-05-31
NZ515053A (en) 2004-02-27
KR20070050979A (ko) 2007-05-16
CA2370814A1 (en) 2000-11-02
IL182908A0 (en) 2007-08-19
RS20080471A (sr) 2010-12-31
CN100360183C (zh) 2008-01-09
BR0010669A (pt) 2002-02-19
HK1041452A1 (en) 2002-07-12
IS6105A (is) 2001-10-11
NO330221B1 (no) 2011-03-07
CN1596979A (zh) 2005-03-23
JP2014065747A (ja) 2014-04-17
CN1356911A (zh) 2002-07-03
JP2007182453A (ja) 2007-07-19
HUP0201015A2 (hu) 2002-07-29
KR100837715B1 (ko) 2008-06-13
HK1076379A1 (zh) 2006-01-20
CN1191860C (zh) 2005-03-09
DK1173201T3 (da) 2005-09-12
EP1173201B1 (en) 2005-06-22
IL206830A0 (en) 2010-12-30
CZ20013754A3 (cs) 2002-07-17
HUP0201015A3 (en) 2004-12-28
PL198975B1 (pl) 2008-08-29
EE05662B1 (et) 2013-06-17
US20020182213A1 (en) 2002-12-05
PL351916A1 (en) 2003-06-30
IS2259B (is) 2007-06-15
WO2000064474A1 (en) 2000-11-02
EA200101116A1 (ru) 2002-04-25
SK287328B6 (sk) 2010-07-07
ES2243259T3 (es) 2005-12-01
MXPA01010612A (es) 2003-09-04
KR20020000221A (ko) 2002-01-05
NO20015122L (no) 2001-12-21
IL145898A0 (en) 2002-07-25
AU783054B2 (en) 2005-09-22
DE60020955T2 (de) 2006-05-11
BG110115A (en) 2008-12-30
IL206829A0 (en) 2010-12-30
NO20015122D0 (no) 2001-10-19
IL206829A (en) 2013-06-27
SK15202001A3 (sk) 2002-09-10
IL182908A (en) 2010-11-30
KR20070102760A (ko) 2007-10-19
BG65578B1 (bg) 2009-01-30
EP1173201A1 (en) 2002-01-23
US20050281818A1 (en) 2005-12-22
HK1041452B (en) 2005-10-14
ATE298249T1 (de) 2005-07-15
PT1173201E (pt) 2005-08-31
CZ301636B6 (cs) 2010-05-12
HU226383B1 (hu) 2008-10-28
AU4480000A (en) 2000-11-10
WO2000064474A8 (en) 2001-04-05
US20040037827A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
TR200200027T2 (tr) İntergrin alfa-4 alt-biriminin bir antagonisti kullanılarak fibrozun tedavisi.
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
DK1268481T3 (da) Inaseinkibitorer som terapeutiske midler
TR200200118T2 (tr) Yeni bileşimler
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
TR200100054T2 (tr) Paroksetin metansülfonat
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
TR199902449T2 (tr) Farmakolojik etkin maddeler.
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DK1152757T3 (da) MMP-inhibitorer i bindevævsblödhed
NO20020626D0 (no) Aktivt, delvis v¶ravhengig forankringssystem
TR200002939T2 (tr) Paroksetin maleat
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
EP1666063A3 (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ES1042492Y (es) Nueva almohadilla para tratar y evitar afecciones cutaneas.
SK2470U (sk) Fotomagnetický stimulátor hojenia
FI20002229L (fi) Menetelmä selkäkivun hoitamiseksi